ASISA Group Met Its Growth Targets in 2025: A Decisive Boost to Insurance and Healthcare Activity

Dr. Francisco Ivorra, president of the ASISA Group, underlined that these results reflected both the positive impact of the new Muface agreement and the effectiveness of the commercial strategy to grow in the private insurance sector. According to the president, the company positioned itself as a more solvent and solid entity, focusing its efforts on the reinvestment of profits for the development of its own healthcare network, the training of its professionals, and the constant improvement of sanitary quality. In the last decade (2016-2025), the Group's accumulated investment amounted to 509.3 million euros, destined entirely to strengthening a health model centered on the patient.

A Record Boost in the Insurance Sector

In the field of insurance, the ASISA Group achieved a new turnover record in Spain with 1,865.84 million euros. The health branch remained the company's main engine, experiencing growth of 21.2% to 1,835.77 million. This performance was explained by a combination of factors: the arrival of more than 65,000 civil servants following the reconfiguration of the mutualist market and a strong advance in private policies. Specifically, the individual segment grew by 9.3%, while SMEs and groups did so by 7.4% and 7.3%, respectively.

For its part, ASISA Vida closed the year with 34.3 million euros in premiums in Spain and Portugal, surpassing 150,000 insured parties. The company consolidated itself as one of the most competitive options in the life risk insurance market, according to sector comparative studies. Likewise, the remaining branches such as accidents, pets, death, and travel assistance contributed a combined turnover of 10.9 million euros. Pet insurance stood out especially, with turnover skyrocketing by 32.8%, reflecting the insurer's capacity to diversify its portfolio and adapt to the new demands of households.

To sustain this growth and guarantee healthcare quality, ASISA maintained its commitment to improving the conditions of its medical panels. In 2025, the insurer applied a 6.5% increase in medical fees, a trend that will continue in 2026 with an average rise of 7.3%. This investment effort represented an accumulated increase of more than 30% over the last five years, a fundamental pillar to guarantee excellence in the care provided by its integrated professionals.

Healthcare Leadership and Technological Vanguard

The Group's healthcare activity, led by the HLA Group, demonstrated exceptional operational performance. With 18 hospitals and 37 medical centers, the network attended more than 3.3 million consultations and performed 178,183 surgical interventions during the year. HLA's strategic plan included continuous investment in infrastructure, executing expansion and renovation works in strategic centers in Seville, Lleida, and Guadalajara.

The commitment to cutting-edge technology was a constant throughout the year. The HLA Clínica Vistahermosa in Alicante integrated the Group's third Da Vinci robot, becoming the first private center in the city to have this robotic surgery tool. In addition, the Group reinforced its service portfolio with high-level specialized units, such as the new headquarters of the Ripoll y De Prado Medical Group in Seville, an institution that held the FIFA medical center of excellence seal and positioned the center as a world leader in traumatology and sports medicine.

The excellence of the HLA Group was endorsed by various external recognitions. Seven of its hospitals were included among the best in private healthcare in Spain by the Healthcare Reputation Monitor (MRS), and the HLA Universitario Moncloa maintained its presence in the ranking of the world's best hospitals by Newsweek magazine. This commitment to quality extended to its network of specialized clinics, which surpassed one hundred centers in areas such as dental health, ophthalmology, audiology, and assisted reproduction.